In
a
head-to-head
study,
Simparica
Trio®
outperformed
NexGard® PLUS
against
the
drug
resistant
heartworm isolate
ZoeLA.*
SimparicaTRIO
and
pyrantel
chewable
Resistant
heartworm
study
results
Six
monthly
doses
of
Simparica
Trio
protected
more
dogs
from infection*
with
the
resistant
heartworm
isolate
ZoeLA
compared
to
NexGard
PLUS
Simparica
Trio
was
more
Simparica
Trio-treated
dogs
had
significantly
lower heartworm counts
than
Nexgard
PLUS-treated
dogst,
and
Simparica
Trio
demonstrated
99.5%
efficacy
Reduce heartworm
disease
transmission
risk
In
this
study,
no
dogs
(0/8)
in
the
Simparica
Trio-treated
group
became microfilaremic
vs 12.5%
of
dogs
(1/8)
in
the NexGard
PLUS
group
Optimized
dose
Simparica
Trio
delivers
a
higher
moxidectin dose
(24-48
than
PLUS
(12-24
which
was more
effective
against
resistant
heartworm
24-48
moxidectin
out
of
dogs
remained uninfected
in
the
Simparica
Tria
group
vs.
2
out
of
dogs
in
the PLUS
group.
98.1%
efficacy
for PLUS
Visit Covetrus.vet/Simparica-Trio
to learn more
